Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765197 | 0.86 | SMN1; SMN2 (0.36) | PRKCISMN1; SMN2ALDH1A1CA2LPL | |
| SCHEMBL23181007 | 0.86 | SMN1; SMN2 (0.36) | PRKCISMN1; SMN2ALDH1A1CA2LPL | |
| SCHEMBL31696659 | 0.85 | MGLL (0.39) | SMN1; SMN2L3MBTL1PLGF12F11 | |
| SCHEMBL23916448 | 0.80 | ENPP2 (0.33) | PLGF12F11KLKB1PRSS1 | |
| SCHEMBL454134 | 0.80 | LOXL2 (0.47) | CA2PLGF12F11KLKB1 | |
| SCHEMBL29526015 | 0.80 | LOXL2 (0.47) | CA2PLGF12F11KLKB1 | |
| SCHEMBL23916450 | 0.77 | ENPP2 (0.30) | ENPP2 | |
| SCHEMBL24023378 | 0.77 | PLCG1 (0.40) | PRKCILMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL31197968 | 0.76 | PRKCI (0.32) | PRKCILMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL1765332 | 0.72 | LMNA (0.44) | PRKCILMNASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220056018-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | CAPULUS THERAPEUTICS, LLC | 2022-02-24 | — | — | US | disclosed |
| EP-3917513-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | Capulus Therapeutics, LLC (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113631163-A | SREBP inhibitors comprising a thiophene central ring | 卡普勒斯疗法有限责任公司 | 2021-11-09 | — | — | CN | disclosed |
| US-20210047340-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | CAPULUS THERAPEUTICS, LLC | 2021-02-18 | — | — | US | disclosed |
| CN-112243374-A | SREBP inhibitors comprising a 6-membered central ring | 卡普勒斯疗法有限责任公司 | 2021-01-19 | — | — | CN | disclosed |
| EP-3746070-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | Capulus Therapeutics, LLC (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020159889-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | CAPULUS THERAPEUTICS, LLC (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2019148125-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | CAPULUS THERAPEUTICS, LLC (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-20130095193-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | SREBF1, SREBF2, XBP1 | PRKCI 639/4885LMNA 499/4885SMN1; SMN2 4012/4885 |
| US-20130095193-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | PRKCI 33/4885LMNA 1721/4885SMN1; SMN2 1436/4885 |
| US-20210047340-A1 | SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING | SREBF1, SREBF2, XBP1 | PRKCI 639/4885LMNA 499/4885SMN1; SMN2 4012/4885 |
| US-20220056018-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | SREBF1, SREBF2, FABP1 | PRKCI 758/4885LMNA 1445/4885SMN1; SMN2 4050/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | PRKCI 1094/4885LMNA 2671/4885SMN1; SMN2 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.